Hypereosinophilic Syndrome - Pipeline Review, H2 2020
Hypereosinophilic Syndrome - Pipeline Review, H2 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypereosinophilic Syndrome - Pipeline Review, H2 2020, provides an overview of the Hypereosinophilic Syndrome (Hematological Disorders) pipeline landscape.
The hypereosinophilic syndrome (HES) is a disease characterized by a persistently elevated eosinophil count (? 1500 eosinophils/mm?) in the blood for at least six months without any recognizable cause, with involvement of either the heart, nervous system, or bone marrow. HES is a diagnosis of exclusion, after clonal eosinophilia (such as leukemia) and reactive eosinophilia (in response to infection, autoimmune disease, atopy, hypoadrenalism, tropical eosinophilia, or cancer) have been ruled out.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypereosinophilic Syndrome - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Hypereosinophilic Syndrome (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hypereosinophilic Syndrome (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypereosinophilic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Phase I stages are 1, 1, 3 and 1 respectively.
Hypereosinophilic Syndrome (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypereosinophilic Syndrome - Pipeline Review, H2 2020, provides an overview of the Hypereosinophilic Syndrome (Hematological Disorders) pipeline landscape.
The hypereosinophilic syndrome (HES) is a disease characterized by a persistently elevated eosinophil count (? 1500 eosinophils/mm?) in the blood for at least six months without any recognizable cause, with involvement of either the heart, nervous system, or bone marrow. HES is a diagnosis of exclusion, after clonal eosinophilia (such as leukemia) and reactive eosinophilia (in response to infection, autoimmune disease, atopy, hypoadrenalism, tropical eosinophilia, or cancer) have been ruled out.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypereosinophilic Syndrome - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Hypereosinophilic Syndrome (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hypereosinophilic Syndrome (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypereosinophilic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Phase I stages are 1, 1, 3 and 1 respectively.
Hypereosinophilic Syndrome (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypereosinophilic Syndrome (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Hypereosinophilic Syndrome (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypereosinophilic Syndrome (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypereosinophilic Syndrome (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypereosinophilic Syndrome (Hematological Disorders)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypereosinophilic Syndrome (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypereosinophilic Syndrome (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Hypereosinophilic Syndrome - Overview
Hypereosinophilic Syndrome - Therapeutics Development
Hypereosinophilic Syndrome - Therapeutics Assessment
Hypereosinophilic Syndrome - Companies Involved in Therapeutics Development
Hypereosinophilic Syndrome - Drug Profiles
Hypereosinophilic Syndrome - Dormant Projects
Hypereosinophilic Syndrome - Discontinued Products
Hypereosinophilic Syndrome - Product Development Milestones
Appendix
Hypereosinophilic Syndrome - Overview
Hypereosinophilic Syndrome - Therapeutics Development
Hypereosinophilic Syndrome - Therapeutics Assessment
Hypereosinophilic Syndrome - Companies Involved in Therapeutics Development
Hypereosinophilic Syndrome - Drug Profiles
Hypereosinophilic Syndrome - Dormant Projects
Hypereosinophilic Syndrome - Discontinued Products
Hypereosinophilic Syndrome - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development for Hypereosinophilic Syndrome, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Hypereosinophilic Syndrome - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2020
Hypereosinophilic Syndrome - Pipeline by Bristol-Myers Squibb Co, H2 2020
Hypereosinophilic Syndrome - Pipeline by GlaxoSmithKline Plc, H2 2020
Hypereosinophilic Syndrome - Pipeline by Incyte Corp, H2 2020
Hypereosinophilic Syndrome - Pipeline by Knopp Biosciences LLC, H2 2020
Hypereosinophilic Syndrome - Pipeline by Kyowa Kirin Co Ltd, H2 2020
Hypereosinophilic Syndrome - Dormant Projects, H2 2020
Number of Products under Development for Hypereosinophilic Syndrome, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Hypereosinophilic Syndrome - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2020
Hypereosinophilic Syndrome - Pipeline by Bristol-Myers Squibb Co, H2 2020
Hypereosinophilic Syndrome - Pipeline by GlaxoSmithKline Plc, H2 2020
Hypereosinophilic Syndrome - Pipeline by Incyte Corp, H2 2020
Hypereosinophilic Syndrome - Pipeline by Knopp Biosciences LLC, H2 2020
Hypereosinophilic Syndrome - Pipeline by Kyowa Kirin Co Ltd, H2 2020
Hypereosinophilic Syndrome - Dormant Projects, H2 2020
LIST OF FIGURES
Number of Products under Development for Hypereosinophilic Syndrome, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
Number of Products under Development for Hypereosinophilic Syndrome, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
